News | November 09, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sumatriptan injection is indicated in adults for the acute treatment of migraine
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Cupid has been allocated approximately 23.4 million units of female condoms per year
RedHill has obtained a court-approved asset attachment in South Korea to prevent Kukbo from transferring or disposing of assets ahead of enforcement of the judgment
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
